Anaveon presents positive ANV600 cancer drug data at ASCO 2026, seeks partners for oncology assets.

Anaveon announced positive Phase 1 clinical data for its cancer drug ANV600, showing safety and early tumor shrinkage benefits, at the ASCO 2026 meeting. ANV600 targets PD-1 to boost immune response against tumors, including in resistant cases, and is compatible with existing therapies. The company is now seeking global partners to develop and commercialize its oncology portfolio while focusing internally on immunology. This move aims to maximize the value of its differentiated cancer treatments and advance Phase 2 trials.